Evidence map›Paper›PMID 34680493›Full record

ArticleBiomedicines2021

From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients.

Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, Antonis Mavromatos, Myrto G Papaioannou, Aikaterini Foska, Ioannis Tollos, Sotirios G Paraskevas, Anastasios Bonakis, Konstantinos I Voumvourakis and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. International journal of molecular sciences · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ioanna Tsantzali2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.ORCID 0000-0002-7582-7059
Fotini BoufidouNeurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Eginition" Hospital, 11528 Athens, Greece.
Eleni Sideri2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Antonis Mavromatos2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Myrto G PapaioannouNeurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Eginition" Hospital, 11528 Athens, Greece.
Aikaterini Foska2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Ioannis Tollos2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Sotirios G ParaskevasNeurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Eginition" Hospital, 11528 Athens, Greece.
Anastasios Bonakis2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Konstantinos I Voumvourakis2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Georgios Tsivgoulis2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
Elisabeth KapakiNeurochemistry and Biological Markers Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Eginition" Hospital, 11528 Athens, Greece.
George P Paraskevas2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.ORCID 0000-0002-2481-3060

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Analysis of classical cerebrospinal fluid biomarkers, especially when incorporated in a classification/diagnostic system such as the AT(N), may offer a significant diagnostic tool allowing correct identification of Alzheimer's disease during life. We describe four patients with more or less atypical or mixed clinical presentation, in which the classical cerebrospinal fluid biomarkers amyloid peptide with 42 and 40 amino acids (Aβ

Indexed as

aducanumabAlzheimer’s diseaseanti-amyloid antibodiesbeta amyloidbiomarkerscerebrospinal fluidphospho-tautau protein

Identifiers

PMID34680493
PMCPMC8533180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.